MAPK3 and breast carcinoma: Recent studies with 2MeOE2 treatment have shown that it induces JNK, Erk-1/2 and p38 activation in breast cancer cells [58], stabilizes SMAD7 and induces p38-MAPK mediated apoptosis in prostate cancer [59] and retinoblastoma cells [49].